Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Navidea Biopharmaceuticals Inc. (NAVB)

0.7101   -0.016 (-2.23%) 11-19 16:00
Open: 0 Pre. Close: 0.7263
High: 0 Low: 0
Volume: 0 Market Cap: 13M
Navidea Biopharmaceuticals Inc is a biotechnology company engaged in precision medicine. Its products are designed to assist in the identification of undetected diseases and develop treatment for cancer, autoimmune conditions, and inflammatory diseases.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.722 - 0.725 0.725 - 0.728
Low: 0.69 - 0.695 0.695 - 0.699
Close: 0.703 - 0.711 0.711 - 0.716

Technical analysis

as of: 2019-11-19 4:28:25 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.29     One year: 1.62
Support: Support1: 0.64    Support2: 0.53
Resistance: Resistance1: 1.10    Resistance2: 1.39
Pivot: 0.81
Moving Average: MA(5): 0.70     MA(20): 0.81
MA(100): 0.67     MA(250): 1.80
MACD: MACD(12,26): -0.02     Signal(9): 0.01
Stochastic oscillator: %K(14,3): 11.79     %D(3): 9.12
RSI: RSI(14): 44.85
52-week: High: 4.40  Low: 0.49  Change(%): -81.3
Average Vol(K): 3-Month: 59398  10-Days: 16760

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
NAVB has closed above bottom band by 26.6%. Bollinger Bands are 69.1% wider than normal. The large width of the bands suggest high volatility as compared to NAVB's normal range. The bands have been in this wide range for 13 bars. This is a sign that the current trend might continue.

Headline News

Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will present at the PCG Spotlight Series Conference taking place on Thursday, November 21st at the Harvard Club, 35 West 44th Street, New York, NY at 12:25pm ET. Mr. Jed A. Latkin, Chief Executive Officer, will be presenting and meeting with investors throughou

Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter ended September 30, 2019. “During the third quarter, Navidea continued to deliver on the Company’s initiatives to complete the NAV 3-31 Phase 2B trial in patients with Rheumatoid Arthritis (“RA”),” said Mr. Jed A. Latkin, Chi

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE American
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 18.08
Shares Float (M) 11.63
% Held by Insiders 21.79
% Held by Institutions 4.85
Shares Short (K) 685
Shares Short P. Month (K)

Stock Financials

EPS -0.930
Book Value (p.s.) -0.040
PEG Ratio
Profit Margin
Operating Margin -1412.49
Return on Assets (ttm) -83.4
Return on Equity (ttm) -1182.6
Qtrly Rev. Growth 2.3
Gross Profit (p.s.) 0.059
Sales Per Share
EBITDA (p.s.) -0.506
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -0.76
P/E Growth Ratio -0.03
P/BV -17.75
P/S 14.20

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2019-04-26
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.